Navigation Links
AtriCure Reports First Quarter 2008 Financial Results
Date:5/6/2008

e of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation (including the purported class action lawsuit) or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com

ATRICURE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended March 31,

2008 2007

Revenues $13,530,145 $10,750,770

Cost of revenues 3,230,880 2,210,495

Gross profit 10,299,265 8,540,275

Operating expenses:

Research and development expenses 2,433,154 3,129,278

Selling, general and

administrative expenses 11,762,426 10,283,187

Total operating
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
2. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
3. Vion Reports 2008 First Quarter Results
4. eResearchTechnology Reports First Quarter 2008 Results
5. MannKind Corporation Reports First Quarter Financial Results
6. Verenium Reports Financial Results for the First Quarter 2008
7. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
8. United Therapeutics Reports First Quarter 2008 Financial Results
9. Endocare Reports 2008 First Quarter Financial Results
10. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
11. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  Caris Life Sciences ® , a leading ... precision medicine, today announced the presentation of data ... of Caris Molecular Intelligence ® , the company,s ... identify targeted treatment options for patients with rare ... results of which are to be presented in ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Translation is frequently ... is for a good reason--if used in a way that ... the offering of a business product or service offering. ... can have a positive effect on a company's bottom line: ... that anyone in the world can use, why not offer ...
(Date:5/28/2015)... DUBLIN , May 27, 2015 /PRNewswire/ ... announced the addition of Jain PharmaBiotech,s new ... to their offering. An ... and biotechnology industries is anticipated. Nanotechnology will ... development - from formulations for optimal delivery ...
(Date:5/28/2015)... N.J. , May 28, 2015 Celsion ... that it has received commitments from two institutional healthcare ... of the Company,s common stock in an at-the-market registered ... to purchase common stock. The Company entered ... to which the Company agreed to sell an aggregate ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Three Ways Translation Can Help Businesses Grow 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3
... to Provide Update on Pipeline Efforts at 27th Annual ... Genomic Health, Inc. (Nasdaq: GHDX ) ... validation study for its 18-gene Oncotype DX(R) colon cancer ... the landmark QUASAR trial, the validation study will use ...
... Achieved A Year Ahead of Schedule , ... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... as part of its agreement with Sigma-Aldrich Corporation (Nasdaq: ... reagents (ZFNs) for research applications. The milestone triggers a ...
... 12 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer ... today announced preliminary revenue,and earnings for the full ... Based upon preliminary data for the fourth quarter, ...
Cached Biology Technology:Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 2Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 3Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 4Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 5Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 2Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 4Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings 2
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... grain production must double by 2050 to address rising ... Illinois suggests crop yields will suffer unless new approaches ... Improved agronomic traits responsible for the remarkable increases in ... their ceiling for some of the world,s most important ...
... Ind. - Chemical engineers at Purdue University have developed ... biomass into biofuels, and they are proposing the creation ... to produce the fuels. "What,s important is ... -- wood chips, switch grass, corn stover, rice ...
... LAFAYETTE, Ind. - A Purdue University researcher can better retrieve ... using a newly developed technique and synthetic nanopolymer. W. ... be mapped and analyzed to find ways to inhibit the ... must be fished out of a sea of thousands of ...
Cached Biology News:'Business as usual' crop development won't satisfy future demand 2'Business as usual' crop development won't satisfy future demand 3New biofuels processing method for mobile facilities 2New biofuels processing method for mobile facilities 3New retrieval method makes studying cancer proteins easier 2
... Fernbach-style culture flasks have triple baffles located ... to achieve maximal oxygen transfer to culture ... spot., A wide range of optional caps ... Polypropylene colored caps for ease of sorting ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
...
... wide mouth PYREX Fernbach-style culture flasks have ... the flask bottom to achieve maximal oxygen ... flasks have a Delong-style 38mm neck for ... For plastic closures see Nos. CLS2679638 or ...
Biology Products: